PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hemophilia A or B
Conditions
Hemophilia A or B
Trial Timeline
Mar 8, 2017 → Dec 3, 2018
NCT ID
NCT02974855About PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086 is a phase 2 stage product being developed by Pfizer for Hemophilia A or B. The current trial status is completed. This product is registered under clinical trial identifier NCT02974855. Target conditions include Hemophilia A or B.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02974855 | Phase 2 | Completed |
Competing Products
20 competing products in Hemophilia A or B
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab + rFVIIa + aPCC | Chugai Pharmaceutical | Phase 3 | 77 |
| Human Coagulation Factor VIII | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab + Factor VIII (FVIII) | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Roche | Phase 3 | 77 |
| HEMLIBRA | Johnson & Johnson | Pre-clinical | 23 |
| Emicizumab | Roche | Phase 3 | 77 |
| Emicizumab | Roche | Approved | 85 |
| Emicizumab | Roche | Phase 3 | 77 |
| SPK-8011QQ | Roche | Phase 1/2 | 41 |
| NXT007 | Roche | Phase 1/2 | 41 |
| Emicizumab Injection | Roche | Phase 2 | 52 |
| Bypassing Agents + FVIII Replacement | Roche | Pre-clinical | 23 |
| Nonacog Alfa (Genetical Recombination) | Pfizer | Pre-clinical | 22 |
| Refacto AF | Pfizer | Pre-clinical | 22 |
| PF-06838435/ fidanacogene elaparvovec | Pfizer | Phase 3 | 76 |
| ReFacto AF | Pfizer | Phase 3 | 76 |
| Nonacog alfa + Nonacog alfa | Pfizer | Phase 3 | 76 |